News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Martin Samuel Bates
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2021 |
4
| Martin Samuel Bates (SVP and CFO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Sold 9,500 shares
@ $42, valued at
$399k
Exercised 3,250 options to buy
@ $9.0165, valued at
$29.3k
Exercised 3,750 options to buy
@ $2.78, valued at
$10.4k
|
|
| 11/17/2021 |
4
| Martin Samuel Bates (SVP and CFO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Sold 7,452 shares
@ $43.923, valued at
$327.3k
Sold 2,048 shares
@ $42.2701, valued at
$86.6k
Exercised 3,250 options to buy
@ $9.0165, valued at
$29.3k
Exercised 3,750 options to buy
@ $2.78, valued at
$10.4k
|
|
| 08/12/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/21/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/19/2020 |
4
| Martin Samuel Bates (SVP and CFO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 105,600 options to buy
@ $10.38, valued at
$1.1M
|
|
| 06/10/2020 |
4
| Martin Samuel Bates (SVP and CFO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Bought 9,750 shares
@ $3.05, valued at
$29.7k
|
|
| 06/20/2019 |
4
| Martin Samuel Bates (SVP and CFO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 43,000 options to buy
@ $2.78, valued at
$119.5k
|
|
| 06/15/2018 |
4
| Martin Samuel Bates (SVP and CFO) has filed a Form 4 on Celldex Therapeutics, Inc.|
Txns:
| Granted 395,000 options to buy
@ $0.6011, valued at
$237.4k
|
|
| 07/05/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
|
|